Insmed Inc (INSM)

[wjlknew]

I hope this meets the criteria for reposting here from YMB.

"pinequin -

You are aware are you not that TRCA has a recent (prior to the delay in EMEA's consideration of Increlex which gave INSM an advantage in Europe) agreement with a European partner which gives the partner the right to sell Increlex in Europe. In return, the European partner bought a large stake in TRCA for approximately $70 million.

I would think this agreement ... and the $70 million ... might be in jeopardy if TRCA cannot, for whatever reason, sell Increlex in Europe. If so, that would explain TRCA's risky strategy of bringing up the European situation.

This is the jist of the agreement:
"Under terms of the collaboration announced on July 18, 2006, Ipsen has granted Tercica exclusive rights to sell Somatuline® Autogel®, a leading product in the European acromegaly market, in the United States, subject to approval by the U.S. Food and Drug Administration (FDA), and in Canada. Tercica has granted Ipsen exclusive rights to sell Increlex(TM), a leading product in the United States for the treatment of short stature associated with severe Primary IGF-1 deficiency (Primary IGFD), in all regions of the world except the United States, Japan, Canada, Taiwan and certain countries of the Middle East and North Africa, subject to approval by relevant regulatory authorities."

For complete PR see:
http://biz.yahoo.com/bw/061016/200610160...

Comments?"